Doravirine/lamivudine/tenofovir explained

Type:combo
Component1:Doravirine
Class1:Non-nucleoside reverse transcriptase inhibitor
Component2:Lamivudine
Class2:Nucleoside reverse transcriptase inhibitor
Component3:Tenofovir disoproxil
Class3:Nucleotide reverse transcriptase inhibitor
Tradename:Delstrigo
Dailymedid:Delstrigo
Routes Of Administration:By mouth
Atc Prefix:J05
Atc Suffix:AR24
Legal Au:S4
Legal Ca:Rx-only
Legal Ca Comment:[1] [2]
Legal Uk:POM
Legal Uk Comment:[3]
Legal Us:Rx-only
Legal Eu:Rx-only
Legal Eu Comment:[4]
Cas Number:2446159-50-6
Kegg:D11396
Synonyms:MK-1439A

Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[5] [6] It contains doravirine, lamivudine, and tenofovir disoproxil.[7] It is taken by mouth.

In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.[8] [9]

External links

Notes and References

  1. Web site: PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION : DELSTRIGO. PDF. Pdf.hres.ca. 5 June 2022.
  2. Web site: Drug and medical device highlights 2018: Helping you maintain and improve your health . . 14 October 2020 . 17 April 2024.
  3. Web site: Delstrigo 100 mg /300 mg /245 mg film-coated tablets - Summary of Product Characteristics (SmPC) . Medicines.org.uk . 8 July 2020 . 1 October 2020.
  4. Web site: Delstrigo EPAR . European Medicines Agency (EMA) . 1 October 2020.
  5. Web site: Delstrigo- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated . DailyMed . 10 October 2019 . 31 July 2020.
  6. 31393687 . Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo) . Ottawa (ON) . ((Canadian Agency for Drugs and Technologies in Health)) . June 2019 . CADTH Common Drug Reviews .
  7. FDA Approves Merck's Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and Pifeltro (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients . Merck & Co. . 30 August 2018.
  8. Web site: Delstrigo approval letter . 2018-08-30 . Food and Drug Administration (FDA) . 10 September 2019 .
  9. Web site: Drug Approval Package: Pifeltro (doravirine) . U.S. Food and Drug Administration (FDA) . 9 October 2018 . 22 September 2020.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Doravirine/lamivudine/tenofovir".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.